Chronic Inflammatory Response Syndrome (CIRS) & Biotoxin Illness in ME/CFS: Shoemaker Biomarkers, HERTSMI-2 & Targeted Binder Protocols

1. The Pathophysiological Triad: Genetics, Innate Immune Activation & Capillary Hypoperfusion

The pathogenesis of CIRS in ME/CFS hinges on a genetically determined defect in antigen presentation. In healthy individuals exposed to foreign biological toxins—such as trichothecenes from Stachybotrys chartarum, ochratoxin A from Aspergillus, or actinomycete endotoxins—dendritic cells present these antigens via Human Leukocyte Antigen (HLA) Class II molecules to naive helper T cells, facilitating antibody formation, neutralization, and hepatic-biliary clearance.

However, approximately 24% of the general population—and up to 78% of severe ME/CFS cohorts—possess genetically susceptible HLA-DRB1, HLA-DQB1, and HLA-DRB3/4/5 haplotypes PMID: 24940263. In these genetically susceptible individuals, the adaptive immune system fails to recognize biotoxins as foreign. Instead of being cleared by neutralizing antibodies, the unflagged, lipophilic biotoxins bind indefinitely to surface pattern recognition receptors (PRRs) on innate immune effector cells, including Toll-like receptors (TLR2, TLR4) and NOD-like receptors (NLRP3 inflammasome).

This persistent ligation triggers an unconstrained, non-antigen-specific inflammatory cascade driven by pro-inflammatory cytokines, complement split products, and matrix-degrading enzymes. These systemic mediators induce extensive capillary endothelial basement membrane thickening, luminal narrowing, and microvascular hypoperfusion across peripheral muscles and cerebral microvessels. The resulting localized tissue ischemia severely impairs mitochondrial oxidative phosphorylation, replicating the hallmark post-exertional malaise (PEM) and profound cognitive dysfunction of ME/CFS PMID: 19854823.

2. The Diagnostic Biomarker Panel & Visual Contrast Sensitivity (VCS) Mechanics

Diagnosing CIRS within an ME/CFS clinical workup requires moving beyond non-specific inflammatory markers like ESR and CRP, which are almost universally normal in biotoxin illness. Dr. Ritchie Shoemaker's peer-reviewed framework establishes a panel of surrogate neuro-immune biomarkers that reflect innate immune hyperactivation, microvascular basement membrane thickening, and neuroendocrine hypothalamic blunting PMID: 28555023:

• Transforming Growth Factor Beta-1 (TGF-β1): Reference range < 2,380 pg/mL. TGF-β1 is a potent regulator of tissue remodeling and extracellular matrix synthesis. When elevated (> 5,000 pg/mL), it causes profound microvascular basement membrane thickening, blunts naive T-cell differentiation, suppresses natural killer (NK) cell cytotoxicity, and promotes pulmonary and parenchymal tissue remodeling.
• Matrix Metalloproteinase-9 (MMP-9): Reference range 85–332 ng/mL. MMP-9 is an inducible zinc-dependent endopeptidase released by inflammatory neutrophils and macrophages. It digests the type IV collagen scaffolding of vascular basements, breaking down the blood-brain barrier (BBB) and allowing circulating neurotoxins to enter cerebral tissue, directly triggering microglial priming and central neuroinflammation.
• Complement Split Product C4a: Reference range < 2,830 ng/mL. An extremely sensitive biomarker of innate complement system activation. In CIRS, C4a surges within hours of water-damaged building exposure, causing microvascular endothelial capillary leakage, plasma volume extravasation, and worsening orthostatic intolerance (POTS).
• Alpha-Melanocyte-Stimulating Hormone (α-MSH): Reference range 35–81 pg/mL. Produced in the paraventricular nucleus of the hypothalamus, α-MSH regulates mucosal immunity, blood-brain barrier integrity, melatonin synthesis, and anti-inflammatory neuro-endocrine tone. In CIRS, hypothalamic hypoperfusion leads to severe α-MSH depletion (< 20 pg/mL), causing mucosal barrier breakdown, unrefreshing sleep, circadian misalignment, and chronic multi-system hyperalgesia.
• Vasoactive Intestinal Peptide (VIP): Reference range 20–59 pg/mL. VIP governs pulmonary arterial hemodynamics, cerebral blood flow regulation, and regulatory T-cell (Treg) induction. Severe VIP depletion (< 15 pg/mL) leads to exercise intolerance, abnormal pulmonary arterial pressures during exertion, and persistent inability to downregulate innate inflammation.
• Visual Contrast Sensitivity (VCS) Deficits: Biotoxin-induced capillary hypoperfusion specifically impairs the high-metabolic-demand columns of the lateral geniculate nucleus and retinal ganglion cells. Standard Snellen visual acuity (20/20) remains intact, but the patient exhibits an inability to discern subtle spatial frequencies in Column D and Column E (12 to 18 cycles per degree). A positive VCS test demonstrates a 92% sensitivity for active biotoxin-mediated neuro-vascular hypoperfusion PMID: 15852570.

3. Step-by-Step Clinical Eradication & Bile-Acid Sequestrant Binder Protocols

Biotoxins undergo extensive enterohepatic circulation: following hepatic glucuronidation, they are secreted via the biliary tree into the duodenum, where up to 95% are rapidly reabsorbed across the intestinal mucosa back into portal circulation. Standard systemic antioxidants and glutathione fail to break this cycle unless an insoluble, high-affinity anion-exchange resin is present in the gut lumen to bind the toxins and eliminate them via stool PMID: 32661168.

Managing the Biotoxin Mobilization Reaction (Herxheimer / Flare)

When sequestrant binders bind biotoxins in the duodenum, the sudden gradient shift mobilizes stored mycotoxins from adipose and deep connective tissues into systemic circulation. This can trigger an acute flare of neuro-inflammation, severe fatigue, orthostatic intolerance, and myalgias.

To mitigate this reaction, clinicians utilize a 2-week pre-treatment priming protocol consisting of:

• High-Dose Omega-3 Fatty Acids: 2,400 mg EPA and 1,800 mg DHA daily to downregulate nuclear factor kappa B (NF-κB) and blunt MMP-9 induction before starting binders.
• Mast Cell Stabilization: Ketotifen (1–2 mg daily) or Quercetin (500 mg TID) to prevent secondary histamine degranulation provoked by mobilized biotoxins.
• Micro-Dosing Sequestrants: Starting CSM at 1 gram every other day dissolved in cold water, slowly escalating only after previous doses are tolerated without unmanageable PEM.

4. Environmental Remediations: ERMI vs. HERTSMI-2 & Safe Habitation Thresholds

Medical therapy with binders is completely ineffective if the patient remains exposed to an active water-damaged building. Airborne mycotoxins and nanometer-scale fungal fragments enter the respiratory tract and cross mucosal barriers within minutes, overwhelming binder capacity.

Standard commercial air-o-cell spore traps are notoriously unreliable for CIRS evaluation because heavy, sticky spores (such as Stachybotrys and Chaetomium) rarely remain airborne in high concentrations unless actively disturbed. Instead, clinicians rely on Quantitative Polymerase Chain Reaction (qPCR) dust analysis:

• ERMI (Environmental Relative Moldiness Index): Developed by the EPA, ERMI quantifies 36 fungal species and compares the ratio of water-damage molds (Group 1) to common outdoor molds (Group 2). A score > 2 represents unacceptable risk for CIRS.
• HERTSMI-2 (Health Effects Roster of Type-Specific Molds): Developed by Dr. Shoemaker, HERTSMI-2 focuses specifically on the 5 most virulent, neurotoxic species found in water-damaged buildings: Stachybotrys chartarum, Chaetomium globosum, Aspergillus versicolor, Aspergillus penicillioides, and Wallemia sebi. A weighted point system assigns scores from 0 to 50:
  • Score < 10: Building is safe for occupancy by CIRS and ME/CFS patients.
  • Score 11–15: Borderline contamination; professional remediation and re-testing mandatory before prolonged exposure.
  • Score > 15: Dangerous environment; highly likely to cause severe symptom relapse and continuous innate immune activation.